00:02 , Dec 7, 2017 |  BC Extra  |  Company News

Management Tracks: Sunesis, Vital

Cancer company Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said President and CEO Daniel Swisher will step down, effective Dec. 31. He will join Jazz Pharmaceuticals plc (NASDAQ:JAZZ) as president and COO. Director Dayton Misfeldt will serve as...
08:00 , Dec 20, 2012 |  BC Innovations  |  Strategy

MRC Technology extends reach

After six years of focusing on developing small molecule drug candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology , the commercialization arm of the country's Medical Research Council , is taking...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Biolex infectious news

Biolex filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the Middle District of North Carolina. According to documents filed on July 3, the company has $803,000 in assets and $38.1 million in...
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

Biolex infectious news

Biolex said it is seeking to sell worldwide rights to its remaining asset, hepatitis candidate Locteron . The controlled-release formulation of recombinant interferon (IFN) alpha-2b completed Phase II testing to treat HCV infection. Details were...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Biolex, Synthon deal

Synthon acquired Biolex's LEX System biologics manufacturing platform and preclinical compounds BLX-155 and BLX-301. The LEX System uses cultures of duckweed Lemna minor to develop pharmaceutical proteins, including glycan-engineered mAbs, biosimilars and follow-on biologics. Biolex...
07:00 , May 2, 2011 |  BioCentury  |  Regulation

Triple standard in HCV

An FDA panel's unanimous endorsement of HCV candidates Victrelis boceprevir from Merck & Co. Inc. and telaprevir from Vertex Pharmaceuticals Inc. last week was hardly a surprise. However, the panel's lukewarm reception for response-guided therapy...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

Locteron: Additional Phase IIb data

Additional data from the international Phase IIb SELECT-2 trial in 116 treatment-naïve HCV patients showed that 320, 480 and 640 µg subcutaneous Locteron every other week led to lower increases in peak mean BDI scores...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Biolex board of directors update

Biolex Therapeutics Inc. , Pittsboro, N.C.   Business: Infectious, Biomanufacturing   Appointed: Kurt Graves as executive chairman, formerly EVP, CCO and head of strategic development of Vertex Pharmaceuticals Inc.  ...
00:27 , Nov 10, 2010 |  BC Extra  |  Company News

Biolex names Graves executive chairman

Infectious disease company Biolex Therapeutics Inc. (Pittsboro, N.C.) appointed Kurt Graves executive chairman, a newly created position. Graves was previously EVP, CCO and head of strategic development at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)....
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Locteron: Additional Phase IIb data

Additional data from the international Phase IIb SELECT-2 trial in 116 treatment-naïve HCV patients showed that a greater proportion of patients receiving 320, 480 and 640 µg subcutaneous Locteron every other week achieved an SVR...